TrialCancer2020

Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.

PierFranco Conte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.